Polycythemia Vera - Pipeline Insight, 2026
Description
DelveInsight’s, “Polycythemia Vera - Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Polycythemia Vera pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Polycythemia Vera: Overview
Polycythemia vera (PV) is a myeloproliferative neoplastic disorder involving uncontrolled red blood cell production resulting in elevated red blood cell (RBC) mass. There is often a concurrent stimulation of myeloid and megakaryocytic lineages, leading to increased white blood cell and platelet production. The current understanding of pathophysiology involves increased sensitivity to growth factors due to an abnormal hematopoietic cell clone. Signs and symptoms, including headache, dizziness, claudication, thrombosis, are a consequence of increased blood viscosity.
The bone marrow of patients with polycythemia vera (PV) contains normal stem cells and contains abnormal clonal stem cells that suppress normal stem cell growth and maturation. The cause of panmyelosis is unregulated neoplastic proliferation. JAK2 kinase mutation likely leads to the signaling derangements resulting in PV. A valine to phenylalanine substitution at position 617 of the JAK2 gene, or JAK2V617F, leads to constitutively active cytokine receptors. This mutation is observed in over 90% of patients with PV and 50% to 60% of primary myelofibrosis, and 50% of essential thrombocythemia. This process leads to increased production of red blood cells and platelets with associated complications of thrombosis and bleeding.
The etiology of the disease process appears to be neoplastic proliferation. There is a signaling defect leading to an abnormal response to growth factors, and the abnormal clonal line interferes with normal lineage proliferation. The Janus kinase-2 (JAK2) gene involved with intracellular signaling is mutated in 90% of cases of polycythemia vera (PV). Cytogenetic studies show the presence of an abnormal karyotype in the hematopoietic progenitor cells in approximately 34% of patients with PV. At the time of diagnosis, 20% of patients have cytogenetic abnormalities, increasing to more than 80% for those with more than 10 years of follow-up care.
The diagnosis of Polycythemia Vera has evolved from the older PVSG criteria to the updated WHO 2016 guidelines. Earlier criteria relied on increased red cell mass, oxygen saturation, splenomegaly, and supportive hematologic parameters, but are now less commonly used due to practical limitations. The current WHO criteria require either all three major criteria or two major plus one minor criterion for diagnosis. Major criteria include elevated hemoglobin/hematocrit levels, bone marrow hypercellularity with trilineage proliferation, and the presence of JAK2 mutations. A low serum erythropoietin level serves as the minor criterion. Importantly, these criteria are applied only after excluding secondary causes of polycythemia. There is no cure for polycythemia vera (PV); treatment goals are aimed at symptom relief and reducing the risk of disease complications, including thrombosis, bleeding, and hematologic transformation. There are currently no means for preventing transformation into myelofibrosis or acute leukemia/myelodysplastic syndrome, but there are known agents to avoid that can increase this risk.
""Polycythemia Vera - Pipeline Insight, 2026"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polycythemia Vera pipeline landscape is provided which includes the disease overview and Polycythemia Vera treatment guidelines. The assessment part of the report embraces, in depth Polycythemia Vera commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polycythemia Vera collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Polycythemia Vera report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Polycythemia Vera Emerging Drugs
Further product details are provided in the report……..
Polycythemia Vera: Therapeutic Assessment
This segment of the report provides insights about the different Polycythemia Vera drugs segregated based on following parameters that define the scope of the report, such as:
Polycythemia Vera: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polycythemia Vera therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycythemia Vera drugs.
Polycythemia Vera Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Polycythemia Vera: Overview
Polycythemia vera (PV) is a myeloproliferative neoplastic disorder involving uncontrolled red blood cell production resulting in elevated red blood cell (RBC) mass. There is often a concurrent stimulation of myeloid and megakaryocytic lineages, leading to increased white blood cell and platelet production. The current understanding of pathophysiology involves increased sensitivity to growth factors due to an abnormal hematopoietic cell clone. Signs and symptoms, including headache, dizziness, claudication, thrombosis, are a consequence of increased blood viscosity.
The bone marrow of patients with polycythemia vera (PV) contains normal stem cells and contains abnormal clonal stem cells that suppress normal stem cell growth and maturation. The cause of panmyelosis is unregulated neoplastic proliferation. JAK2 kinase mutation likely leads to the signaling derangements resulting in PV. A valine to phenylalanine substitution at position 617 of the JAK2 gene, or JAK2V617F, leads to constitutively active cytokine receptors. This mutation is observed in over 90% of patients with PV and 50% to 60% of primary myelofibrosis, and 50% of essential thrombocythemia. This process leads to increased production of red blood cells and platelets with associated complications of thrombosis and bleeding.
The etiology of the disease process appears to be neoplastic proliferation. There is a signaling defect leading to an abnormal response to growth factors, and the abnormal clonal line interferes with normal lineage proliferation. The Janus kinase-2 (JAK2) gene involved with intracellular signaling is mutated in 90% of cases of polycythemia vera (PV). Cytogenetic studies show the presence of an abnormal karyotype in the hematopoietic progenitor cells in approximately 34% of patients with PV. At the time of diagnosis, 20% of patients have cytogenetic abnormalities, increasing to more than 80% for those with more than 10 years of follow-up care.
The diagnosis of Polycythemia Vera has evolved from the older PVSG criteria to the updated WHO 2016 guidelines. Earlier criteria relied on increased red cell mass, oxygen saturation, splenomegaly, and supportive hematologic parameters, but are now less commonly used due to practical limitations. The current WHO criteria require either all three major criteria or two major plus one minor criterion for diagnosis. Major criteria include elevated hemoglobin/hematocrit levels, bone marrow hypercellularity with trilineage proliferation, and the presence of JAK2 mutations. A low serum erythropoietin level serves as the minor criterion. Importantly, these criteria are applied only after excluding secondary causes of polycythemia. There is no cure for polycythemia vera (PV); treatment goals are aimed at symptom relief and reducing the risk of disease complications, including thrombosis, bleeding, and hematologic transformation. There are currently no means for preventing transformation into myelofibrosis or acute leukemia/myelodysplastic syndrome, but there are known agents to avoid that can increase this risk.
""Polycythemia Vera - Pipeline Insight, 2026"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polycythemia Vera pipeline landscape is provided which includes the disease overview and Polycythemia Vera treatment guidelines. The assessment part of the report embraces, in depth Polycythemia Vera commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polycythemia Vera collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Polycythemia Vera R&D. The therapies under development are focused on novel approaches to treat/improve Polycythemia Vera.
This segment of the Polycythemia Vera report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Polycythemia Vera Emerging Drugs
- Bomedemstat: Merck Sharp & Dohme LLC
- Flonoltinib: Chengdu Zenitar Biomedical Technology Co., Ltd
- PRT12396: Prelude Therapeutics
Further product details are provided in the report……..
Polycythemia Vera: Therapeutic Assessment
This segment of the report provides insights about the different Polycythemia Vera drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Polycythemia Vera
- There are approx. 20+ key companies which are developing the therapies for Polycythemia Vera. The companies which have their Polycythemia Vera drug candidates in the most advanced stage, i.e. phase III include, Merck Sharp & Dohme LLC.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Polycythemia Vera: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polycythemia Vera therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycythemia Vera drugs.
Polycythemia Vera Report Insights
- Polycythemia Vera Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Polycythemia Vera drugs?
- How many Polycythemia Vera drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polycythemia Vera?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polycythemia Vera therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Polycythemia Vera and their status?
- What are the key designations that have been granted to the emerging drugs?
- Merck Sharp & Dohme LLC
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Prelude Therapeutics
- Italfarmaco
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Silence Therapeutics plc
- Incyte Corporation
- Hangzhou GluBio Pharmaceutical Co., Ltd.
- Ajax Therapeutics, Inc.
- Syntara
- Bomedemstat
- Flonoltinib
- PRT12396
- Givinostat
- 9MW3011
- SLN-124
- INCB000928
- GLB-001
- AJ1-11095
- PXS-5505
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Polycythemia Vera: Overview
- Introduction
- Signs and Symptoms
- Causes
- Pathophysiology
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Polycythemia Vera– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Bomedemstat: Merck Sharp & Dohme LLC
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Flonoltinib: Chengdu Zenitar Biomedical Technology Co., Ltd
- Product Description
- Research and Development
- Product Development Activities
- Early Stage Products (Phase I)
- Comparative Analysis
- PRT12396: Prelude Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Polycythemia Vera Key Companies
- Polycythemia Vera Key Products
- Polycythemia Vera- Unmet Needs
- Polycythemia Vera- Market Drivers and Barriers
- Polycythemia Vera- Future Perspectives and Conclusion
- Polycythemia Vera Analyst Views
- Polycythemia Vera Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
